Welcome to our dedicated page for Oruka Therapeutics news (Ticker: ORKA), a resource for investors and traders seeking the latest updates and insights on Oruka Therapeutics stock.
Oruka Therapeutics, Inc. (NASDAQ: ORKA) is a clinical-stage biotechnology company developing novel biologics for chronic skin diseases, and its news flow reflects the progress of a focused dermatology pipeline. Company press releases highlight advances for its lead monoclonal antibodies ORKA-001 and ORKA-002, both engineered to target key immunology pathways in plaque psoriasis and related conditions while enabling infrequent dosing.
News updates frequently cover clinical milestones such as Phase 1 interim data, initiation and enrollment of Phase 2 trials, and detailed designs of the EVERLAST-A and EVERLAST-B studies of ORKA-001 in moderate-to-severe plaque psoriasis. Oruka also reports on the first-in-human trial of ORKA-002, including pharmacokinetic and pharmacodynamic findings that support potential twice-yearly dosing in psoriasis and quarterly dosing in hidradenitis suppurativa.
In addition to pipeline developments, Oruka’s news includes quarterly financial results, corporate updates, and capital-raising activities, such as a private placement financing described in company communications. Governance and leadership items, including board appointments and executive promotions, are disclosed through both press releases and Form 8-K filings. The company also announces participation in major healthcare and investor conferences, where it presents clinical data and corporate overviews.
Investors and observers following ORKA news can expect coverage of clinical trial data readouts, regulatory milestones such as IND clearance, financing transactions, and changes in leadership or board composition. This page aggregates those updates so readers can monitor how Oruka’s psoriatic disease programs and broader antibody portfolio evolve over time.
Oruka Therapeutics (Nasdaq: ORKA), a clinical-stage biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its participation in the upcoming Jefferies Global Health Care Conference. The presentation is scheduled for Wednesday, June 4th, 2025, at 12:50 PM ET in New York. Investors and interested parties can access the presentation webcast and replay through Oruka's investor events website at ir.orukatx.com.
Oruka Therapeutics (NASDAQ: ORKA) has begun dosing healthy volunteers in its Phase 1 trial of ORKA-002, a novel half-life extended monoclonal antibody targeting IL-17A/F for treating chronic skin diseases. The trial will evaluate safety, tolerability, and pharmacokinetics across three subcutaneous dose cohorts with approximately 24 participants.
The company expects to share interim data around year-end 2025 and plans to initiate a Phase 2 study in moderate-to-severe psoriasis in 1H 2026. Preclinical data suggests ORKA-002 could enable dosing two to three times per year for psoriasis patients, marking a significant improvement over current standard of care. The planned Phase 2 study will assess multiple dose levels with a primary endpoint of PASI 100 at week 16.
Oruka Therapeutics (NASDAQ: ORKA) reported its Q1 2025 financial results and provided updates on its pipeline programs. The company ended Q1 with a strong cash position of $373 million, providing runway through 2027. Key highlights include:
Their lead program ORKA-001, an IL-23p19 antibody, completed Phase 1 dosing with data expected in Q3 2025. Phase 2a initiation is planned for 2H 2025, with efficacy readout in 2H 2026. The company's second program, ORKA-002, targeting IL-17A/F, has accelerated its Phase 1 initiation to Q2 2025.
Financial results showed R&D expenses of $19.9 million and G&A expenses of $5.2 million for Q1 2025. The company reported a net loss of $21.0 million, which includes $4.9 million in non-cash stock-based compensation.
Oruka Therapeutics (Nasdaq: ORKA), a clinical stage biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, will present at the Bank of America Securities 2025 Health Care Conference.
The presentation is scheduled for Tuesday, May 13th, 2025, at 3:55 PM PT. The company, based in Menlo Park, California, is working to establish new treatment standards in dermatology.
Oruka Therapeutics (ORKA) has revealed promising preclinical data for ORKA-002, their novel extended half-life monoclonal antibody targeting IL-17A/F, at the 2025 AAD Annual Meeting. The drug demonstrated a remarkable half-life of over 30 days in non-human primates - more than triple that of bimekizumab.
Key findings show that ORKA-002 could potentially enable dosing intervals of once every four months to twice yearly in humans, based on projected pharmacokinetics. The drug exhibits equivalent potency and similar binding affinity to bimekizumab, binding IL-17A and IL-17F with comparable picomolar affinity.
The company plans to dose the first subject with ORKA-002 in Q3 2025. The drug is being developed for treating chronic skin diseases, including plaque psoriasis and psoriatic arthritis.
Oruka Therapeutics (ORKA) reported its Q4 and full year 2024 financial results, highlighting significant progress in its clinical pipeline. The company's lead candidate ORKA-001, a novel IL-23p19 antibody, entered Phase 1 trials in December 2024, with PK data expected in 2H 2025 and Phase 2a initiation planned for 2H 2025.
Financial highlights include raising over $475 million in 2024 and ending the year with $393.7 million in cash and equivalents, providing runway through 2027. Q4 2024 showed R&D expenses of $25.5 million and G&A expenses of $4.8 million, with a net loss of $25.8 million.
The company's second candidate, ORKA-002, targeting IL-17A/F, is advancing with Phase 1 initiation expected in Q3 2025. Preclinical data will be presented at the 2025 AAD Annual Meeting. Additionally, Oruka disclosed ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001, and plans to reveal details about ORKA-003 in 1H 2025.
Oruka Therapeutics (Nasdaq: ORKA), a clinical stage biotechnology company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its participation in two major investor conferences in March 2025.
The company will present at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4th, 2025, at 10:30 AM ET, and at the Leerink Global Healthcare Conference on Wednesday, March 12th, 2025, at 8:40 AM ET.
Investors can access the webcasts and replays of these presentations through Oruka's investor events website at https://ir.orukatx.com/news-events/events-presentations.
Oruka Therapeutics (ORKA) has begun dosing healthy volunteers in its Phase 1 trial of ORKA-001, a novel half-life extended monoclonal antibody targeting IL-23p19 for treating chronic skin diseases. The trial will evaluate safety, tolerability, and pharmacokinetics in approximately 24 healthy volunteers across three subcutaneous dose cohorts.
Initial data is expected in H2 2025, followed by a proof-of-concept study in moderate-to-severe psoriasis. The subsequent study will involve about 80 subjects testing six-month and potential yearly dosing schedules, with initial efficacy data anticipated in H2 2026.
Preclinical data suggests potential for once- or twice-yearly dosing, representing a significant improvement over current standards. The company has also secured a worldwide exclusive license agreement with Paragon Therapeutics for ORKA-001 in all indications except inflammatory bowel disease.
Oruka Therapeutics (Nasdaq: ORKA), a biotechnology company focused on developing novel biologics for chronic skin diseases treatment, has announced its upcoming addition to the Nasdaq Biotechnology Index (NBI). The inclusion will be effective before market open on December 23rd, 2024. This addition reflects Oruka's meeting of specific eligibility criteria, including minimum market capitalization requirements, average daily trading volume thresholds, and public company seasoning period. The NBI tracks performance of biotechnology and pharmaceutical companies listed on Nasdaq, using a modified capitalization-weighted methodology with annual evaluation in December.
Oruka Therapeutics (Nasdaq: ORKA), a biotech company focused on developing novel biologics for chronic skin diseases including plaque psoriasis, has announced its upcoming participation at Piper Sandler's 36th Annual Healthcare Conference. The company will engage in a fireside chat scheduled for Tuesday, December 3rd, 2024, at 3:00 PM ET.
FAQ
What is the current stock price of Oruka Therapeutics (ORKA)?
What is the market cap of Oruka Therapeutics (ORKA)?
